Good morning to all. I'm extremely happy to be here today to present these numbers. Our Q3 is a strong one. It is the strongest Q3 in the company's history.
If we exclude one Covid test supported quarter back in the day. So we are delivering and we are delivering at LTM 12.31, a year ahead of schedule. And it's not only that one, but if you look throughout all of our numbers, this is the sixth consecutive quarter that we've improved 62% up on EBITDA year on year. EPS four times net debt standing at 2.3, which is probably an all-time low for this group. So not only are we delivering adjusted EBITDA, delivering EPS, delivering cash flow, and seeing very strong NPS numbers, we also provide essentially effective medical care. We are not doing this at the cost of something. We are doing it because we are this good. If we then look at the numbers, the Finnish segments are clearly delivering healthcare services, both growing and improving margins materially. Portfolios are not showing growth in revenues but are improving the margin exactly as we have planned. Sweden's profit improvement program is on schedule, but we don't yet see the numbers going in the right direction. But if you analyze the numbers carefully, you can already see some very modest sequential improvement. And with all of this, the guidance range has been narrowed. Now, our full year guidance for adjusted EBITDA margin is between 12 and 12.5. So we have cut down the lower end of the margin range given in the summer. But let's go a bit more into the details.
Revenue growth is driven by strong supply, improved sales mix, successful commercial actions, and an early flu season start. So we see clearly in the healthcare services, both appointments and diagnostics are delivering solid sales. Other service sales are slightly wobbling downwards, but there's nothing materially to worry about on that one. There is a bit of seasonality and then we have been renewing, for example, our operating theaters in camp, which has an impact on our operations. Obviously, then if we think a bit further about the growth, we are up in visits, roughly 3% up in visits. And at the same time, we had one additional working day. But even taking that one into account, we are still a couple of percentage points upwards, and the early start of the flu season contributes to that. But it's not the only explanation. We are also growing organically now at the appointment levels, which is very positive for our business. And then at the same time, it's not only appointments and diagnostics, it's true across all customer groups. So, positive performance from Healthcare Services when it comes to revenues in Portfolio Business. We can say that essentially, we have intentionally chosen to decline revenue in the public sector. Part of that involves Outsourcing, which we know very well. And at the same time, the staffing continues. The continuation of the storyline from the first six months that we have already detailed. So, we have deliberately chosen not to bid for everything. We want to keep our margin structure on a healthy base, and therefore, we have also implemented some revenue reduction. Consumer market. Dental massage continues to be at a lower level. Like I said earlier, it has probably bottomed out in February, but at the same time, we don't see any material improvement during the quarter. Demand remains low and continues at that level. Sweden. We have some terminated customer contracts, partly by choice and partly in the public sector. Tendering and the demand environment continue to be weak. There are some hints that it could get more positive, but at the same time it is a fragile environment from a demand perspective. But with all of this, we delivered €296 million in revenues in Q3 compared to €281 million the previous year. Then, if we go into the profitability aspect of Healthcare Services, we have implemented cost measures, established an efficiency program, and maintained a robust sales mix. But what is very important to understand is that we now have a far more balanced margin mix. So we are now, after all of the efficiency actions that we have taken, able to deliver solid margins throughout our different services, whether it's appointments, diagnostics, or operations and so on. We deliver margin and that essentially reduces the risk associated with our seasonality and supports our margin delivery. Then, the early flu season has a positive impact. It's roughly 2000 appointments per week from somewhere around mid-August onwards that we have gained compared to the previous year. Then, if we look at the portfolio of businesses, we see positive development, especially in the public sector, because we have been able to gain efficiencies. We had some loss-making old contracts that support us, or at least low margin contracts. And when those are out of the system, it supports the relative profitability. But it's not only that one; it's also growing in absolute terms. In Sweden, we are facing reduced revenue and cost inflation pressures. But once again, I reiterate we are progressing as planned in the profit improvement program. You are already beginning to see very modest hints on that part. If you think about it now, our Q3 revenues are declining a bit less than our year-to-date revenues. So now we are stabilizing out there. And at the same time, if you look at our number of people, if you look at the cost structure, we have taken some hard measures that are starting to be visible in the numbers. Step by step, we are moving forward. But having said that, Q4 will be difficult, and in 2025 we will be in a better position to make profits in Sweden. This picture you have seen, you will continue seeing it in the future. But what can I say? Story continued; thus, materially, nothing new in this one. In Healthcare Services, all customer groups or payer groups are growing in revenues. There is a hefty five percentage point improvement in margin. Also, portfolio businesses are almost doubling their margins. But the revenue is consistently going downwards. And Sweden, as explained, we are progressing in there, but it still takes further time year to year. To date, we have seen substantial improvement. Our big machine is ticking. And also here, I would like to highlight the consistency. We have been delivering these numbers now for six quarters in a row, and we have been progressing consistently quarter by quarter to reach this point. And now we are on 12.6. Year to date, adjusted EBITDA margins are at 12.3 over the last 12 months. Then if we think about the balance sheet side of things and our cash position, we are taking almost €200 million of operating cash flow during the quarter. This basically correlates with our operating margin improvement. The more we deliver EBITA, the more we deliver cash, and that operates like clockwork. Then, it's important to note that currently the gross CapEx stands at €37 million. On a 12-month basis, that is a low number. We have been repeatedly saying that it should be between 4 to 4.5 percentage points from the revenue, and at the same time, our eyes are turning more and more to organic growth, and that will require investments.
So, we foresee that we have positive business cases to invest in organic growth. And potentially, the CapEx level will get higher in the future, but we will come back to that one also at the Capital Markets Day on December 4th. Net debt to adjusted EBITDA stands at 2.3. As I said, I think that it's at an all-time low during the history of this group, highlighting the cash generation, but also reminding all of us and all of you that we have the capability to invest if there are positive cases. Then, let's talk about the guidance. So basically, the first part of the guidance, as you know, is that we are expecting the revenues to grow. Now we have narrowed the range to 12 to 12.5. Then, if you look at the first five bullets, they are pretty much the same as they have been continuously, excluding the fifth bullet. Last statements. So now if you put this guidance into context, let's say that you would calculate the implied range for Q4 from here, year to date 12.6, ending up at 12 to 12.5 in a full year. You pretty much get into the mid-tens on the lower end and low twelves on the higher end of the guidance range. And that would indicate that Q4 would not be operationally great. But then you need to read the fifth bullet's final statements. We have some one-time items, not as adjustment items, but items that are now coming in the fourth quarter. We have the collateral labor agreement, where we have the one-time impact of €500 per employee that will be paid in December, and then we have a one-off payment to all staff that will be paid out in the fourth quarter, which will also affect the performance of the fourth quarter. Even with all of this in mind, it is fair to say the scenarios pointing to the upper end of the range seem to be more likely than any that would suggest the lower end of the range. So we are doing well also in Q4, but with these one-time items, I think it's time for Q&A and also a reminder about the commercial CMD on the 4th of December.